David A. Siegel Travere Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 700,200 shares of TVTX stock, worth $5.76 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
700,200
Previous 542,800
29.0%
Holding current value
$5.76 Million
Previous $4.88 Million
10.64%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding TVTX
# of Institutions
184Shares Held
89.5MCall Options Held
66.9KPut Options Held
265K-
Black Rock Inc. New York, NY7.8MShares$64.1 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.5MShares$61.7 Million0.79% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.37MShares$60.6 Million1.88% of portfolio
-
State Street Corp Boston, MA6.61MShares$54.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.27MShares$51.5 Million0.0% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $528M
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...